Actively Recruiting
Multicenter Post-Market Observational Registry of the NeoChord Artificial Chordae Delivery System
Led by NeoChord · Updated on 2020-07-10
500
Participants Needed
5
Research Sites
407 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The objective of this study is to evaluate the 5-year outcomes of participants with degenerative mitral valve disease treated with the NeoChord Artificial Chordae System, Model DS1000 in a post-market setting.
CONDITIONS
Official Title
Multicenter Post-Market Observational Registry of the NeoChord Artificial Chordae Delivery System
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Has Grade III Moderate or Grade IV Severe degenerative or mixed disease mitral valve regurgitation
- Study procedure completed after 31 December 2016
You will not qualify if you...
- Heavily calcified valves
- Valvular retraction with severely reduced mobility
- Active bacterial endocarditis
- Complex mechanism of mitral regurgitation such as leaflet perforation
- Significant tethering of leaflets
- Inflammatory valve disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
University of Bonn
Bonn, Germany
Actively Recruiting
2
CVC Frankfurt
Frankfurt, Germany
Actively Recruiting
3
University of Mainz
Mainz, Germany
Actively Recruiting
4
Hippokration Hospital
Athens, Greece
Actively Recruiting
5
Triemli Hospital
Zurich, Switzerland
Actively Recruiting
Research Team
A
Alexandar Jonkers
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here